Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment

Simple item page
dc.authorscopusid23062131200
dc.authorscopusid57464431900
dc.authorscopusid56042671700
dc.authorscopusid6701728553
dc.authorscopusid56286078700
dc.authorscopusid23984071100
dc.authorscopusid35095964200
dc.contributor.authorTerzi, M.
dc.contributor.authorHelvacı, E.M.
dc.contributor.authorŞen, S.
dc.contributor.authorBoz, C.
dc.contributor.authorÇilingir, V.
dc.contributor.authorAkçalı, A.
dc.contributor.authorBeckmann, Y.
dc.contributor.authorÜnal, Aysun
dc.date.accessioned2023-05-06T17:23:34Z
dc.date.available2023-05-06T17:23:34Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.description.abstractIntroduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey. Method: The first generic fingolimod efficacy and safety data of patients followed-up in 29 different clinical multiple sclerosis units in Turkey were analyzed retrospectively. Data regarding efficacy and safety of the patients were transferred to the data system both before the treatment and on the 6th, 12th and 24th month following the treatment. The data were analyzed using the IBM SPSS 20.00. P value of <0.05 was considered to be statistically significant. Results: A total of 508 multiple sclerosis patients, 331 of whom were women, were included in the study. Upon comparing the Expanded Disability Status values before and after the treatment, a significant decrease was observed, especially at month 6 and thereafter. Since bradycardia occurred in 11 of the patients (2.3%), the first dose had to be longer than 6 hours. During the observation of the first dose, no issues that could prevent the use of the drug occured. Side effects were seen in 49 (10.3%) patients during the course of fingolimod treatment. Respectively, the most frequent side effects were bradycardia, hypotension, headache, dizziness and tachycardia. Conclusion: The observed results regarding efficacy and safety were similar to clinical trial data in the literature and real life data in terms of the first equivalent with fingolimod active ingredient. © 2023, Turkish Neuropsychiatric Society. All rights reserved.
dc.description.sponsorshipThanks to SANOVEL for funding the publication process.
dc.identifier.doi10.29399/npa.28081
dc.identifier.endpage27
dc.identifier.issn1300-0667
dc.identifier.issue1en_US
dc.identifier.pmid36911568
dc.identifier.scopus2-s2.0-85151017784
dc.identifier.scopusqualityQ3
dc.identifier.startpage23
dc.identifier.trdizinid1169769
dc.identifier.urihttps://doi.org/10.29399/npa.28081
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12157
dc.identifier.volume60
dc.identifier.wosWOS:001190959500002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorÜnal, Aysun
dc.language.isoen
dc.publisherTurkish Neuropsychiatric Society
dc.relation.ispartofNoropsikiyatri Arsivi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEfficacy
dc.subjectfingolimod
dc.subjectmultiple sclerosis
dc.subjectsafety
dc.subjectdimethyl fumarate
dc.subjectfingolimod
dc.subjectteriflunomide
dc.subject25 step walking test
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectblood pressure
dc.subjectbody mass
dc.subjectbradycardia
dc.subjectclinical evaluation
dc.subjectcontusion
dc.subjectdemographics
dc.subjectdigit symbol substitution test
dc.subjectdizziness
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug withdrawal
dc.subjectExpanded Disability Status Scale
dc.subjectfemale
dc.subjectfollow up
dc.subjectheadache
dc.subjectheart infarction
dc.subjecthuman
dc.subjecthypertransaminasemia
dc.subjecthypotension
dc.subjectleukocyte count
dc.subjectlipid fingerprinting
dc.subjectlymphocyte count
dc.subjectlymphocytopenia
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmultiple sclerosis
dc.subjectnine hole peg test
dc.subjectnuclear magnetic resonance imaging
dc.subjectpaced auditory serial addition test
dc.subjectpruritus
dc.subjectretrospective study
dc.subjecttachycardia
dc.titleClinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12157.pdf
Size:
639.94 KB
Format:
Adobe Portable Document Format
Description:
Tam Metin / Full Text
Download

Collections

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize